<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Several prognostic factors for patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) have been defined in the past </plain></SENT>
<SENT sid="1" pm="."><plain>One of these factors appears to be the serum <z:chebi fb="4" ids="24996">lactate</z:chebi> dehydrogenase (LDH) activity </plain></SENT>
<SENT sid="2" pm="."><plain>However, the precise predictive value of an <z:mp ids='MP_0002944'>elevated LDH level</z:mp> with regard to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> transformation remains uncertain </plain></SENT>
<SENT sid="3" pm="."><plain>In this study, the prognostic value of the LDH activity was examined in a cohort of 180 patients with de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (median age 71 years [27-93]; f/m-ratio 1:1.2; RA: n=53; <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>: n=37; <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>: n=50; <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEBT</z:e>: n=19; <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>: n=21) </plain></SENT>
<SENT sid="4" pm="."><plain>Significant differences in LDH activities were found among FAB groups (P&lt;0.05), and especially among IPSS groups (HIGH: 411+/-574; INT-2: 221+/-90; INT-1: 254+/-145; LOW: 192+/-47 U/l; P&lt;0.05) </plain></SENT>
<SENT sid="5" pm="."><plain>An LDH level of &gt;/=300 U/l was found to be associated with a significantly shorter median survival (10.3 months) when compared to &lt;300 U/l (33.7 months; P&lt;0.01) </plain></SENT>
<SENT sid="6" pm="."><plain>Moreover, an LDH activity of &gt;/=300 U/l indicated a reduced <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-free survival in our <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients (P&lt;0.01) </plain></SENT>
<SENT sid="7" pm="."><plain>As assessed by Cox regression, the inclusion of LDH as additional variable into the IPSS system resulted in an improved prediction concerning survival, but not with regard to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> evolution </plain></SENT>
<SENT sid="8" pm="."><plain>Together, our data show that a serum LDH activity of &gt;/=300 U/l in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> is associated with a significantly shorter survival and higher risk to transform to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>The LDH activity should be considered as an important prognostic factor in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>